These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36152755)

  • 21. Choice of Dose Level for a Randomized Clinical Trial of Low-Dose Bevacizumab vs Laser for Type 1 Retinopathy of Prematurity.
    Kraker RT; Wallace DK; Beck RW; Saunders CT; Lorenzi E; Melia BM; Li Z;
    JAMA Ophthalmol; 2021 Oct; 139(10):1143-1144. PubMed ID: 34410311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis.
    Ortiz-Seller A; Martorell P; Barranco H; Pascual-Camps I; Morcillo E; Ortiz JL
    Surv Ophthalmol; 2024; 69(4):585-605. PubMed ID: 38432359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
    Sindal MD; Nagesha CK; Yadav D; Fazal R
    Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report.
    Taylor K; Ghergherehchi L; Rao P; Harper CA; Chang E
    J AAPOS; 2021 Jun; 25(3):180-184. PubMed ID: 33964455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I.
    Yoon JM; Shin DH; Kim SJ; Ham DI; Kang SW; Chang YS; Park WS
    Retina; 2017 Jan; 37(1):88-96. PubMed ID: 27347645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
    Gunay M; Sukgen EA; Celik G; Kocluk Y
    Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful Surgical Management of Retinopathy of Prematurity Showing Rapid Progression despite Extensive Retinal Photocoagulation.
    Gadkari SS; Kulkarni SR; Kamdar RR; Deshpande M
    Middle East Afr J Ophthalmol; 2015; 22(3):393-5. PubMed ID: 26180484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
    Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
    Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atypical case of retinopathy of prematurity with candle wax-like preretinal deposits and its surprising response to intravitreal antivascular endothelial growth factor.
    Shah MS; Padhy SK; Sahu S; Padhi TR
    BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical glycerine for corneal clouding during retinal laser photocoagulation for retinopathy of prematurity.
    Lambat S; Gupta S; Nagar R; Nangia P; Dogra M; Nangia V
    Eur J Ophthalmol; 2023 Jul; 33(4):1755-1757. PubMed ID: 36703255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.
    Kıran Yenice E; Petriçli İS; Kara C
    Int Ophthalmol; 2023 Jul; 43(7):2197-2202. PubMed ID: 36522564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.
    Moran S; O'Keefe M; Hartnett C; Lanigan B; Murphy J; Donoghue V
    Acta Ophthalmol; 2014 Sep; 92(6):e496-7. PubMed ID: 24428792
    [No Abstract]   [Full Text] [Related]  

  • 34. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
    Han J; Kim SE; Lee SC; Lee CS
    Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP).
    Wutthiworawong B; Thitiratsanont U; Saovaprut C; Subhangkasen I; Geyuraphun B; Ampornprut A; Phumongkutchai J; Tephusdinnaayuthaya S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S15-21. PubMed ID: 22043749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.
    Nicoară SD; Ștefănuţ AC; Nascutzy C; Zaharie GC; Toader LE; Drugan TC
    Med Sci Monit; 2016 Apr; 22():1192-209. PubMed ID: 27062023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series.
    Martínez-Castellanos MA; González-H León A; Romo-Aguas JC; Gonzalez-Gonzalez LA
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):767-772. PubMed ID: 31953595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity.
    Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO
    Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Commentary: Are we there yet? Role of anti-vascular endothelial growth factor and laser in the management of retinopathy of prematurity.
    Sindal MD; Yadav D
    Indian J Ophthalmol; 2021 Aug; 69(8):2176-2177. PubMed ID: 34304204
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of supplemental oxygen in reducing the need for laser or intravitreal bevacizumab in preterm infants with stage 2 retinopathy of prematurity.
    Minturn R; Hartigan K; Vegunta S; Boente C; Golzarri-Arroyo L; Hynes E; Laughlin E; Haider K; Kua KL
    BMC Ophthalmol; 2024 May; 24(1):220. PubMed ID: 38790043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.